Portal de Periódicos da CAPES

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

2021; Taylor & Francis; Volume: 62; Issue: 12 Linguagem: Inglês

10.1080/10428194.2021.1948031

1042-8194

Tomás Palanques-Pastor, Juan Eduardo Megías‐Vericat, Pilar Martı́nez, José Luis López Lorenzo, Javier Cornago Navascués, Gabriela Rodríguez Macias, Isabel Cano, Montserrat Arnán Sangerman, María Belén Vidriales Vicente, Jesús Lorenzo Algarra, María Ángeles Foncillas, Pilar Herrera, Carmen Botella Prieto, Susana Vives, Ángela Figuera Álvarez, Laida Cuevas Palomares, Marta Sobas, Alejandro Gonzalo, Rebeca Cuello García, María Elena Amutio Diez, D. de Miguel Llorente, Begoña Navas Elorza, Juan Bergua, Teresa Bernal, María Carmen Mateos Rodriguez, Erik de Cabo, A Villegas, Raimundo García Boyero, Cristián Escolano Escobar, Cristina Seri Merino, Carlos Cerveró, Alicia Roldán, Lourdes Hermosín Ramos, Marta Cervera Calvo, María Telesa Olave, Paola Villafuerte Gutiérrez, Almudena de Laiglesiai, Josefina Serrano, María Josefa Najera Irazu, José Luís Piñana, Miguel Á. Sanz, Joaquín Martínez‐López, Pau Montesinos,

Hematological disorders and diagnostics

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March–May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.